Company Filing History:
3 out of 2,930 
1 out of 45 Years Active: 2017-2021
Title: Innovations of Christopher R Cogle
Introduction
Christopher R Cogle is a notable inventor based in Gainesville, FL (US), recognized for his contributions to the field of medical research and therapeutic compounds. With a total of three patents to his name, Cogle has made significant strides in developing new treatments for serious diseases, particularly cancer.
Latest Patents
Cogle's latest patents include "Polyamine sulfonamides and uses thereof," which addresses the critical need for new antineoplastic agents. This invention relates to therapeutic compounds with antineoplastic activity, specifically polyamine sulfonamides that can be used in the treatment and prevention of cancer. The patent also outlines pharmaceutical compositions and methods for inducing apoptosis in cells and inhibiting alpha-enolase enzymatic activity. Another significant patent is "Myxoma-treated graft material for cancer treatment," which provides a method for treating or preventing graft versus host disease (GVHD) in subjects receiving grafts comprising hematopoietic cells. This method involves using Myxoma Virus to inhibit T lymphocyte proliferation in the graft, thereby preventing GVHD after the graft is infused into the subject.
Career Highlights
Cogle has worked with esteemed organizations such as the University of Florida Research Foundation and the Torrey Pines Institute for Molecular Studies. His work in these institutions has allowed him to focus on innovative research that aims to improve cancer treatment outcomes.
Collaborations
Throughout his career, Cogle has collaborated with notable colleagues, including Douglas Grant McFadden and Eric C Bartee. These collaborations have contributed to the advancement of his research and the development of his patented inventions.
Conclusion
Christopher R Cogle's innovative work in the field of cancer treatment exemplifies the importance of research and development in addressing unmet medical needs. His patents reflect a commitment to improving therapeutic options for patients facing serious health challenges.